www.StockMarketingInc.com: Wake Up People!! Sign Up For The Free Newsletter!! WZE: "Wizzard Media Launches 24 New iPhone Apps"

(NYSE: WZE - Wizzard Software Corp.)

(NASDAQ: IGOI - iGo, Inc.)

(NASDAQ: RNOW - RightNow Technologies, Inc.)

(NASDAQ: DPTR -Delta Petroleum Corp.)

(NASDAQ: ITMN - InterMune, Inc.)

(PINKSHEETS: SNSS aEUR" Sunesis Pharmaceuticals, Inc.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NYSE: WZE - Wizzard Software Corp.)

LATEST NEWS!!

Wizzard Media Launches 24 New iPhone Apps

PITTSBURGH, Nov 05, 2009 -- Wizzard Media (NYSE Amex: WZE), the world's largest podcasting network, today announced the launch of 24 new iPhone(R) Apps available for sale in the App store including Investors Business Daily Editorials and Alaska HDTV. The average price for the new Apps is $1.99.

The newly launched Apps are iPhone companion Apps for popular podcasts on the Wizzard Media Network, offering audiences one-click access to the podcast directly on their iPhone or iPod Touch(R), bonus content and new social communication features creating an unprecedented level of audience engagement.

Wizzard recently announced 2009 third quarter network numbers of 12,281 podcasts downloaded 332 million times in the quarter by over 18 million unique monthly audience members. Approximately 70% of the audience for podcasts subscribe through iTunes(R) from which users download podcasts for their iPhone and iPod(R). Until recently, Wizzard's only means to derive revenues was through podcast publishing services as well as advertising sales.

With the launch of the iPhone App store in iTunes, Wizzard created a unique iPhone App that can be quickly customized for each podcast and allows podcast publishers to generate a new revenue stream by marketing their own iPhone App directly to their audience. Wizzard shares in this revenue with the podcast publisher. Now, with Wizzard's unique podcast companion App for the iPhone, participating podcasts can market their customized App to their audience and then drive future reoccurring episode and subscription sales through a process called in-App purchasing.

Analysts project the App market to be a $1.0 billion market today, headed for $4.0 billion by 2012. With the holiday season approaching and the recent launch of the iPhone in China, Wizzard's Management believes the number of people using iPhones and iPod Touches to consume podcasts and interact with Apps will continue to grow well beyond the current 50 million user base.

Having launched the first podcast App only 95 days ago, Wizzard Media already has launched 70 iPhone Apps with 60 more Apps awaiting approval. Additionally, Wizzard has exclusively licensed 12 high quality, game type Apps and is currently marketing them through targeted podcasts across the Wizzard Media Network. Select podcast Apps on the Wizzard Network have already helped to convert approximately 15% of their audience from free, to paid, in the first 75 days since launch.

"We think our podcast companion App initiative is a game changer for the podcasting industry. We believe the next great opportunity on the web for media is the seamless combination of three trends -- publishing services, advertising and micropayments for App sales," says Dave Mansueto, co-founder Wizzard Media. "Now, podcasting becomes a platform that converts audiences to revenue, accelerated by the micropayment billing process that Apple has created with the App store. We believe this new process is the model for how digital media is published, audiences are grown and revenues derived." "We know there is strong demand for the podcasts we distribute seeing downloads grow from 400 million to well over 1 billion in the last three years and monthly audiences grow from 4 million to 18 million," says Laurie Sims, President of Wizzard Media. "Now that we have a method to charge for podcast content and subscriptions, we believe there is dramatic change ahead for the podcast industry. Unlike most Apps in the App store, podcasters have a distinct advantage to successfully market their App in iTunes due to the fact that they have already built a substantial audience for their product through iTunes." About Wizzard Media: Wizzard Media provides publishing and distribution services to podcasters and monetization services for podcasters. Wizzard Media is the industry's leading podcasting network with an unprecedented 1.2 billion download requests in 2008. Podcasts are a means for independent and professional content creators to publish audio and video shows for the world to enjoy over the Internet or on mp3 players, such as the Apple iPod(R), iPhone(R) and the Microsoft Zune(R). Podcasting is a relatively new phenomenon, but Wizzard Media collectively broadcasts millions of podcast downloads per day through media aggregators like Apple's iTunes and Microsoft's Zune Marketplace. For more information, please visit www.wizzardsoftware.com/media . Wizzard Media is a division of Wizzard Software, a leader in speech technology distribution and development.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: IGOI - iGo, Inc.)

LATEST NEWS!!

STAPLES Canada adds iGo(R) Power Management Solutions to its Shelves

SCOTTSDALE, Ariz., Nov 05, 2009 -- iGo (Nasdaq: IGOI), a leading provider of power management solutions, today announced that STAPLES Canada is now offering iGo products in more than 300 of its stores. iGo products offer a solution for managing the power needs of every consumer, business owner, and business traveler -- whether they need to charge multiple devices simultaneously, reduce their power consumption, or ensure they can power all of their most important devices when traveling internationally.

STAPLES Canada now carries the following iGo products: -- iGo Laptop Wall Charger -- Slim -- iGo's ultra-slim wall charger that powers virtually any model of laptop computer. The included USB cable also charges mobile devices such as mobile phones, MP3 players and more.

-- iGo International Travel Adapter -- an easy to use 4-in-1 international travel adapter for use in the Americas, the United Kingdom, Europe, the Middle East, Asia, Africa and many other regions. The built-in USB power port enables charging of all laptops, digital cameras, smartphones, MP3 players and more.

STAPLES Canada is Canada's largest supplier of office supplies, business machines, office furniture, and business services for the small business and home office customer. The company has over 13,500 employees serving customers through more than 300 office superstores, catalogue and e-commerce.

About iGo, Inc.

iGo, Inc., based in Scottsdale, Arizona, is a leading provider of power management solutions, including eco-friendly chargers for laptop computers, netbooks and mobile electronic devices (e.g., mobile phones, PDAs, digital cameras, etc.). All of these chargers leverage iGo's intelligent tip technology, which significantly minimizes electronic waste by enabling one charger to power/charge hundreds of brands and thousands of models of mobile electronic devices through the use of interchangeable tips. iGo is also the creator of a new, innovative patent-pending power saving technology that automatically eliminates virtually all wasteful and expensive standby or "vampire" power that is generated from chargers that continue to draw electricity when a mobile electronic device no longer requires charging or is disconnected from the charger.

iGo's products are available at www.iGo.com as well as through leading resellers and retailers. For additional information call 480-596-0061, or visit www.igo.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: RNOW - RightNow Technologies, Inc.)

LATEST NEWS!!

RightNow Offers Free Migration to All Kana Customers

Customer Service Leader Provides Kana Clients with Low-Risk Alternative for Delivering Great Customer Experiences

BOZEMAN, Mont., Nov 05, 2009 -- RightNow Technologies (NASDAQ:RNOW) is offering Kana clients free migration services as an alternative to the uncertain future they face as a result of its acquisition by Accel-KKR, a technology-focused private equity firm.

Recently, many Kana clients have replaced Kana with RightNow and have seen an increase in operational savings, plus higher customer satisfaction rates.

"At drugstore.com our service is our brand, so delivering a fast and excellent customer experience is critical. Since moving to RightNow, our agents have a single interface that allows them to help customers quickly and efficiently. We have been able to reduce our call handle times by 20 percent; this translates into not only savings, but better customer experiences." Ron Kelly, vice president, customer and pharmacy services, drugstore.com "We have been consistently replacing Kana for some time; organizations are looking for robust customer experience solutions that deliver significant operational savings and enable them to engage with consumers when and where they want." Jason Mittelstaedt, chief marketing officer, RightNow Click here to learn more about RightNow's solutions.

About RightNow RightNow is helping rid the world of bad experiences one consumer interaction at a time, seven million times a day. RightNow CX, the customer experience suite, helps organizations deliver exceptional customer experiences across the web, social networks and contact centers, all delivered via the cloud. With more than eight billion customer interactions delivered, RightNow is the customer experience fabric for nearly 2,000 organizations around the globe. To learn more about RightNow, go to www.rightnow.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: DPTR -Delta Petroleum Corp.)

LATEST NEWS!!

Delta Petroleum Corporation Announces Third Quarter 2009 Operating Results

DENVER, Nov 05, 2009 -- Delta Petroleum Corporation (Nasdaq: DPTR), an independent oil and gas exploration and development company, announced its financial and operating results for the third quarter of 2009.

GRAY 31-23 COMPLETION RESULTS Delta has finished completion efforts on the Gray well. As previously announced, while all zones encountered significant high pressure, they flowed primarily water with minor amounts of non-commercial associated gas. Additional testing was performed in the basalt section of the well with a similar outcome, and therefore the Gray well has been expensed as a dry hole in the Company's third quarter financial statements.

Delta's Columbia River Basin team has reviewed available data in order to provide possible explanations regarding the lack of commercial gas from the Wenatchee sands of the Gray well. One of the challenges generally experienced in the industry is the fact that fresh water and hydrocarbons are almost indistinguishable on electric logs. Therefore the gas shows and over-pressured reservoir seen in the Gray well during drilling suggested a gas reservoir with some associated water; however, completion results instead revealed that the reservoir is a fresh water reservoir with some associated natural gas.

The lessons learned from the drilling of the Gray well have provided the Company with important and strategic information that will be of benefit in any future drilling operations in the Columbia River Basin. Numerous issues related to drilling through the basalt formation were identified, analyzed and explained, and management believes that this information can be translated into potentially significant savings of both cost and time in the future. While gas was liberated, no source rock was drilled in this well, thus Delta's primary objective, the deeper Roslyn formation, remains a viable target.

John Wallace, the Company's President and COO said, "We are extremely disappointed with the results of the Gray well, but exploration drilling carries with it significant risks. We continue to believe that the Roslyn formation, which has produced elsewhere in the Columbia River Basin, has significant potential and should be tested. In addition, data obtained during the drilling of the Gray well has allowed for better seismic interpretation that can now be applied to the Company's leasehold in the basin. A more accurate representation of the structural configuration below the basalt section, including the Roslyn formation, will help direct us to more precise geologic prospects and potential future well locations." "While much attention was paid to the drilling and completion of the Gray well, we want to highlight to our stockholders where the intrinsic value lies within Delta. Delta's operational strength is in the Rockies and go forward strategy focused on lower-risk development projects will allow the Company to realize consistent, efficient reserve and production growth in the Piceance Basin, once natural gas prices recover. We believe that we have the track record, experience and assets that will allow us to execute this strategy." Dan Taylor, the Company's Chairman stated, "Delta will continue to strive to deliver value to our shareholders through the development of our core assets and the execution of our cost control strategy. I concur with John on the underlying value of Delta being our proved and probable reserves in the Piceance Basin, which are not adequately reflected in our current share price."

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ITMN - InterMune, Inc.)

LATEST NEWS!!

InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone

BRISBANE, Calif., Nov 05, 2009 -- InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior leadership team to prepare for the potential commercialization of pirfenidone in the United States and Europe.

The company announced yesterday that it had submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of IPF. The company expects to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) in the first quarter of 2010. Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe. Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "Today's announcement underscores our commitment to be prepared to bring pirfenidone to patients, should our NDA and/or MAA be granted approval by the regulatory authorities in the United States and Europe, respectively. We are very pleased to have recruited such a high quality team of senior level commercial professionals. Further expansion of our commercial infrastructure will be driven by the outcome of key regulatory events expected in 2010." US and EU Commercial Leadership Appointments InterMune announced the following additions to its leadership team: -- Vice President, Sales - Ms. Terri Shoemaker has held senior commercial leadership positions at Du Pont Pharmaceuticals, Bristol-Myers Squibb, Pharmion and Celgene. Most recently at Pharmion (acquired by Celgene), Ms. Shoemaker was responsible for creating the commercial organization and the successful launch of Vidaza(R), a chemotherapeutic agent for treating myelodysplastic syndrome and some types of leukemia. She later was promoted to Executive Director, Strategic Commercial Operations at Celgene.

-- Vice President, Marketing - Mr. Erik Harris has held senior positions in marketing and sales management at Bristol-Myers Squibb, Genentech and Elan. At Genentech, he held sales and marketing management positions, notably as Group Brand Manager for Rituxan(R) and Tarceva(R). Most recently at Elan, he was a Senior Director of Marketing and Sales in Gastroenterology prior to becoming Senior Director of Strategic Brand Management for Gastroenterology and Neurology. Mr. Harris will assume his responsibilities with InterMune on November 16, 2009.

-- Vice President, Managed Care and Access - Mr. Darren Cline has held senior sales, marketing and managed care roles at Schering-Plough, Amgen, InterMune and most recently, Alexion. At Alexion, he served as Executive Director of Sales and played an integral role in the successful launch of Soliris(R). While at Amgen, Mr. Cline led a managed care team during the launches of Aranesp(R) and Neulasta(R) and was the Reimbursement and Access Marketing Director for Enbrel(R).

-- These three executives will report to Barrett McGrath, who was announced as InterMune's Vice President of Sales and Marketing on August 6, 2009.

With nearly 30 years of experience in the industry, Mr. McGrath has held leadership positions in sales, marketing and business development at Genentech, Du Pont Pharmaceuticals, American Hospital Supply Corporation (now Baxter) and Quintiles Transnational.

-- The company also announced today that Mr. Giacomo di Nepi has been appointed to the newly created position of Senior Vice President and General Manager, Europe. Mr. di Nepi held senior roles at the global and country management levels with Novartis. After Novartis, Mr. di Nepi was the EU General Manager for Takeda where he led EU operations and geographic expansion. Prior to Takeda and Novartis, he was a partner at McKinsey & Co., specializing in healthcare. Mr. di Nepi will report to Mr. Welch.

About Pirfenidone Preclinical and in-vitro evidence had shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. Results from three adequate and well-controlled Phase 3 studies have shown evidence of a treatment effect in IPF patients and the compound has been safe and generally well tolerated, with side effects including photosensitivity rash and gastrointestinal symptoms.

InterMune licensed pirfenidone from Marnac, Inc. and its co-licensor, KDL GmbH, in 2002 and in 2007 purchased from Marnac and KDL the rights to sell the compound in the United States, Europe and other territories except in Japan, Taiwan and South Korea where rights to the molecule were licensed by Marnac and KDL to Shionogi & Co. Ltd. of Japan. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa(R) by Shionogi in that country.

About IPF Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects approximately 200,000 patients in the United States and Europe combined, with approximately 30,000 new cases reported per year in each of the United States and Europe.

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women. There are no medicines approved in the United States or Europe for IPF.

About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and has submitted a New Drug Application (NDA) to the FDA. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (RG7227) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: SNSS - Sunesis Pharmaceuticals, Inc.)

LATEST NEWS!!

Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Nov 05, 2009 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

"This designation recognizes the acute need for more options in treating this poor-prognosis disease," stated Steven B. Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis. "We believe voreloxin has the potential to impact the standard of care for AML and we continue to be encouraged by our progress. We are finalizing a registration strategy for voreloxin in AML and anticipate launching a pivotal trial in 2010." Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides eligibility for a seven-year period of market exclusivity in the United States after product approval and an exemption from user fees.

About Voreloxin Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com
e-mail: info@StockMarketingInc.com
Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Wizzard Software Corp (WZE) WZE. Wizzard Software Corp (WZE) has Short Term PowerRatings at TradingMarkets. Details on Wizzard Software Corp (WZE) Short Term PowerRatings is available at This Link.